Bioventus Inc.
Company Stats
- Market Cap
- $1.1B
- as of Sep 30, 2026
- Shares Outstanding
- 84.1M
- Free Float
- 19.6%
Income Statement
- Revenue
- $568.1M
- Operating Income
- $54.0M
- Net Income
- $22.7M
- EBITDA
- $101.0M
- Revenue Growth, 3Y
- 3.5%
- FCF Margin, 3Y Avg
- 6.9%
- FCF Margin, Worst Year
- 1.6%
Cash Flow
- Free Cash Flow
- $72.1M
- FCF Yield
- 6.3%
- Owner FCF Yield
- 5.2%
Balance Sheet
- Cash & Equivalents
- $51.2M
Returns & Capital
- SBC, 3Y Avg
- $9.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $568.1M | $72.1M | 12.7% |
| FY2024 | $573.3M | $37.8M | 6.6% |
| FY2023 | $512.3M | $8.0M | 1.6% |
| FY2022 | $512.1M | -$15.0M | -2.9% |
| FY2021 | $430.9M | $9.5M | 2.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back